Home — Ignyta Granted Breakthrough Therapy Designation for Entrectinib by U.S. Food and Drug Administration

Ignyta Granted Breakthrough Therapy Designation for Entrectinib by U.S. Food and Drug Administration

San Diego, 15.05.2017

Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted a Breakthrough Therapy Designation (BTD) to entrectinib "for the treatment of NTRK fusion-positive, locally advanced or metastatic solid tumors in adult and pediatric patients who have either progressed following prior therapies or who have no acceptable standard therapies."

Read